Navigation Links
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
Date:8/5/2008

-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular

Edema-

SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.

IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."

About Icon Bioscience, Inc.

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug delivery technology encompasses over twenty related but distinct novel and proprietary drug delivery systems optimally suited for application in the ophthalmic market. The nature of ophthalmic disease and the unique anatomical and physiological features of the eye, combined with the extreme fragility of the eye, dictate that identifying the correct pharmaceutical agent for a specific disease state represents only half the solution. The pharmaceutical agent must be delivered in a manner that maximizes clinical efficacy while minimizing costs and adverse effects. IBI's lead product, IBI-20089, is in Phase I clinical trials for the treatment of cystoid macular edema.

Contact: Icon Bioscience, Inc.

William S. (Sandy) White

Phone: 408-734-8188 Ext. 14

Email: sandywhite@iconbioscience.com


'/>"/>
SOURCE Icon Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed to ... states and Washington, D.C. as part ... that was commended by shareholder advocacy organization As You Sow. ... You Sow. "Many people hold on to unneeded drugs because ... have tragic consequences." --> Conrad MacKerron , ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... and PORTLAND, Ore. , ... 340B optimization company, is pleased to announce the acquisition ... sole community and rural access hospitals. Along with providing ... of 340B consulting services to assist clients in navigating ... R. Love , CEO of Wellpartner. --> ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... Every winter, someone is killed, injured or loses a home in an accident ... of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, and Monroeville ... , “Space Heaters Need Space” aims to bring awareness to the risks ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... the Pittsburgh metro area, celebrates the beginning of the latest charity campaign in ... social skills through art. Donations to this worthy cause are currently being accepted ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... For ... Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. ... joined dozens of dental professionals, donating their time and skills to help hundreds of ...
(Date:2/12/2016)... OR (PRWEB) , ... February 12, 2016 , ... ... an article about foods choices that promote eye health. These articles generally list ... health. Water and health advocate Sharon Kleyne endorses every one of these lists ...
Breaking Medicine News(10 mins):